Clinical Report: Identification of an Oxidative Phosphorylation Profile in Ovarian Cancer

Overview

This study identifies oxidative phosphorylation as a critical metabolic pathway in ovarian cancer, linking it to prognosis, immune cell infiltration, and drug response. A novel oxidative phosphorylation-related gene signature (OPRGS) was developed, showing significant correlations with tumor microenvironment characteristics and chemotherapy resistance.

Background

Ovarian cancer (OC) is a highly heterogeneous disease with poor prognosis, often diagnosed at advanced stages. Understanding the metabolic pathways involved in OC is essential for developing effective prognostic biomarkers and therapeutic targets. This study explores the role of oxidative phosphorylation in OC, highlighting its implications for patient outcomes and treatment strategies.

Data Highlights

No numerical data available in the provided material.

Key Findings

• Oxidative phosphorylation (OXPHOS) was identified as a core metabolic pathway in ovarian cancer.
• The OXPHOS-related gene signature (OPRGS) serves as a reliable risk factor for ovarian cancer prognosis.
• High-risk scores correlated with an immunosuppressive tumor microenvironment and lower immunophenoscores for PD-1 and CTLA-4.
• Higher OPRGS was associated with lower cancer stemness indices and resistance to paclitaxel, but sensitivity to carboplatin.
• KIF1A was identified as a key gene, upregulated in OC cell lines, promoting cell proliferation and invasion.

Clinical Implications

The OPRGS may serve as a valuable prognostic tool for assessing patient outcomes in ovarian cancer, guiding treatment decisions. Understanding the metabolic characteristics of OC can help tailor therapeutic strategies, particularly in relation to chemotherapy resistance and immune evasion.

Conclusion

The identification of OXPHOS as a significant pathway in ovarian cancer underscores the need for further research into metabolic reprogramming and its impact on treatment outcomes. The findings may enhance prognostic assessments and inform therapeutic approaches in clinical practice.

Related Resources & Content

1. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC
2. FDA Fully Approves Mirvetuximab Soravtansine-Gynx for FR Alpha–Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Oncology Nursing Society
3. Cancer resistance and metastasis are maintained through oxidative phosphorylation - ScienceDirect
4. Integration of Molecular Signatures from Tumor Deposits Using Machine Learning Enhances Prognostic Assessment in Colon Adenocarcinoma
5. International Journal of Colorectal Disease — Integrative bioinformatics and machine learning approaches identify novel diagnostic signatures for oxaliplatin-resistant colorectal cancer
6. asco ai in oncology — Multimodal Model Uses Pathology Data to Predict Immunotherapy Response in NSCLC
7. asco ai in oncology — Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
8. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update - PMC
9. FDA Fully Approves Mirvetuximab Soravtansine-Gynx for FR Alpha–Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Oncology Nursing Society
10. Cancer resistance and metastasis are maintained through oxidative phosphorylation - ScienceDirect